TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Svea Vaccin AB
Closing information (x1000 EUR)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
18,095
|
15,200
|
22,868 |
Financial expenses |
5
|
0
|
4 |
Earnings before taxes |
1,492
|
1,685
|
5,068 |
EBITDA |
1,513
|
1,620
|
5,095 |
Total assets |
4,166
|
3,348
|
6,491 |
Current assets |
3,860
|
3,052
|
6,220 |
Current liabilities |
2,426
|
1,866
|
2,428 |
Equity capital |
1,581
|
1,394
|
4,063 |
- share capital |
9
![]() |
9
|
10 |
Employees (average) |
91
|
65
|
80 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
38.0%
|
41.6%
|
62.6% |
Turnover per employee |
199
|
234
|
286 |
Profit as a percentage of turnover |
8.2%
|
11.1%
|
22.2% |
Return on assets (ROA) |
35.9%
|
50.3%
|
78.1% |
Current ratio |
159.1%
|
163.6%
|
256.2% |
Return on equity (ROE) |
94.4%
|
120.9%
|
124.7% |
Change turnover |
2,850
|
-5,815
|
12,206 |
Change turnover % |
19%
|
-28%
|
114% |
Chg. No. of employees |
26
|
-15
|
31 |
Chg. No. of employees % |
40%
|
-19%
|
63% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.